Effect of obesity on gastrointestinal transit, pressure and pH using a wireless motility capsule.


Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 13 04 2021
revised: 22 06 2021
accepted: 07 07 2021
pubmed: 18 7 2021
medline: 13 1 2022
entrez: 17 7 2021
Statut: ppublish

Résumé

Despite the increasing prevalence and medical burden of obesity, the understanding of gastrointestinal physiology in obesity is scarce, which hampers drug development. To investigate the effect of obesity and food intake on gastrointestinal transit, pressure and pH. An exploratory cross-sectional study using a wireless motility capsule (SmartPill©) was performed in 11 participants with obesity and 11 age- and gender-matched participants with normal weight (group) in fasted and fed state (visit). During the first visit, the capsule was ingested after an overnight fast. During a second visit, the capsule was ingested after a nutritional drink to simulate fed state. Linear mixed models were constructed to compare segmental gastrointestinal transit, pressure and pH between groups (obesity or control) and within every group (fasted or fed). Food intake slowed gastric emptying in both groups (both P < 0.0001), though food-induced gastric contractility was higher in participants with obesity compared to controls (P = 0.02). In the small intestine, a higher contractility (P = 0.001), shorter transit (P = 0.04) and lower median pH (P = 0.002) was observed in participants with obesity compared to controls. No differences were observed for colonic measurements. Obesity has a profound impact on gastrointestinal physiology, which should be taken into account for drug development.

Sections du résumé

BACKGROUND BACKGROUND
Despite the increasing prevalence and medical burden of obesity, the understanding of gastrointestinal physiology in obesity is scarce, which hampers drug development.
AIM OBJECTIVE
To investigate the effect of obesity and food intake on gastrointestinal transit, pressure and pH.
MATERIAL AND METHODS METHODS
An exploratory cross-sectional study using a wireless motility capsule (SmartPill©) was performed in 11 participants with obesity and 11 age- and gender-matched participants with normal weight (group) in fasted and fed state (visit). During the first visit, the capsule was ingested after an overnight fast. During a second visit, the capsule was ingested after a nutritional drink to simulate fed state. Linear mixed models were constructed to compare segmental gastrointestinal transit, pressure and pH between groups (obesity or control) and within every group (fasted or fed).
RESULTS RESULTS
Food intake slowed gastric emptying in both groups (both P < 0.0001), though food-induced gastric contractility was higher in participants with obesity compared to controls (P = 0.02). In the small intestine, a higher contractility (P = 0.001), shorter transit (P = 0.04) and lower median pH (P = 0.002) was observed in participants with obesity compared to controls. No differences were observed for colonic measurements.
CONCLUSION CONCLUSIONS
Obesity has a profound impact on gastrointestinal physiology, which should be taken into account for drug development.

Identifiants

pubmed: 34273543
pii: S0939-6411(21)00183-1
doi: 10.1016/j.ejpb.2021.07.002
pii:
doi:

Substances chimiques

Capsules 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

N Steenackers (N)

Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. Electronic address: Nele.steenackers@kuleuven.be.

L Wauters (L)

Translational Research Center for Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. Electronic address: Lucas.wauters@kuleuven.be.

B Van der Schueren (B)

Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. Electronic address: Bart.vanderschueren@kuleuven.be.

P Augustijns (P)

Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: Patrick.augustijns@kuleuven.be.

G Falony (G)

Rega Institute, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; Center for Microbiology, VIB, Leuven, Belgium. Electronic address: Gwen.falony@kuleuven.be.

M Koziolek (M)

Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany. Electronic address: mirko.koziolek@abbvie.com.

M Lannoo (M)

Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium. Electronic address: Matthias.lannoo@kuleuven.be.

A Mertens (A)

Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. Electronic address: Ann.mertens@kuleuven.be.

A Meulemans (A)

Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. Electronic address: Ann.meulemans@kuleuven.be.

J Raes (J)

Rega Institute, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; Center for Microbiology, VIB, Leuven, Belgium. Electronic address: Jeroen.raes@kuleuven.be.

R Vangoitsenhoven (R)

Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. Electronic address: Roman.vangoitsenhoven@kuleuven.be.

S Vieira-Silva (S)

Rega Institute, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; Center for Microbiology, VIB, Leuven, Belgium. Electronic address: Sara.vieirasilva@kuleuven.be.

W Weitschies (W)

Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany. Electronic address: werner.weitschies@uni-greifswald.de.

C Matthys (C)

Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. Electronic address: Christophe.matthys@kuleuven.be.

T Vanuytsel (T)

Translational Research Center for Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium. Electronic address: Tim.vanuytsel@kuleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH